Vernal keratoconjunctivitis treated with omalizumab: a case series
01 Pubblicazione su rivista
Occasi Francesca, Duse Marzia, Nebbioso Marcella, DE CASTRO Giovanna, Di Fraia M, Capata Giulia, Lollobrigida V, Zicari Am.
DOI: 10.1111/pai.12737
ISSN: 1399-3038
We report the cases of four children affected by Vernal keratoconjunctivitis (VKC) treated with Omalizumab with resolution of ocular
signs and symptoms. Vernal keratoconjunctivitis (VKC) is a chronic conjunctivitis, not responding to topical antihistamines and frequently
misdiagnosed and mistreated. The effect of Omalizumab in patients with VKC should be better investigated and well-
designed studies are warranted to prove its efficacy. Not only might these studies be useful in order to provide new therapeutic strategies especially in patients resistant to cyclosporine and tacrolimus, but also they could help to clarify the pathogenesis of this severe ocular disease